Selective biologics for ulcerative colitis and crohn’s disease - Clinical utility of vedolizumab

Biologics: Targets and Therapy

Volumn 10, Issue , 2016, Pages 33-52

  Petkau, Jill M V ^a   Eksteen, Bertus ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

Adhesion molecule antagonist; Anti 4 7 integrin; Inflammatory bowel disease; Leukocyte trafficking; Monoclonal antibody; Selective gut immunotherapy; Tumor necrosis factor alpha

Indexed keywords

ADALIMUMAB; ALPHA4BETA7 INTEGRIN; AZATHIOPRINE; BUDESONIDE; CCL25 CHEMOKINE; CD103 ANTIGEN; CERTOLIZUMAB PEGOL; CHEMOKINE; CHEMOKINE RECEPTOR CCR9; CHOLERA VACCINE; ETROLIZUMAB; GOLIMUMAB; HEPATITIS B VACCINE; INFLIXIMAB; INTEGRIN; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; MONOCLONAL ANTIBODY; MUCOSAL ADDRESSIN CELL ADHESION MOLECULE 1; NATALIZUMAB; PF 00547659; PLACEBO; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VEDOLIZUMAB;

ABDOMINAL PAIN; ARTHRALGIA; ARTHRITIS; BACTERIAL INFECTION; BIOLOGICAL THERAPY; BLOOD DYSCRASIA; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL DISEASE ACTIVITY INDEX; CLINICAL TRIAL (TOPIC); CONGESTIVE HEART FAILURE; COUGHING; CROHN DISEASE; DEMYELINATING DISEASE; DISEASE SEVERITY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG SPECIFICITY; DRUG TARGETING; FATIGUE; HEADACHE; HEPATITIS B; HUMAN; IMMUNOTHERAPY; INFLUENZA; INTESTINE INFECTION; LEUKOCYTE MIGRATION; LYMPHOMA; MAINTENANCE THERAPY; META ANALYSIS (TOPIC); MYCOSIS; NONHUMAN; OPPORTUNISTIC INFECTION; PARASITOSIS; PEPTOCLOSTRIDIUM DIFFICILE; PHARMACEUTICAL CARE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIMARY SCLEROSING CHOLANGITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; RHINOPHARYNGITIS; SEROCONVERSION; TREATMENT INDICATION; TUBERCULOSIS; ULCERATIVE COLITIS; UPPER RESPIRATORY TRACT INFECTION; VIRUS INFECTION;

EID: 84961171050     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: 10.2147/BTT.S71679     Document Type: Review

References (85)

1. The impact of inflammatory bowel disease in Canada: 2012 final report and recommendations. 2012. Available from: http://www.isupportibd.ca/pdf/ccfc-ibd-impact-report-2012.pdf. Accessed July 4, 2015.
2. Fast facts: the impact of IBD in Canada 2012. 2012. Available from: http://isupportibd.ca/pdf/ccfc.ca-impact-report-fast-facts.pdf. Accessed July 4, 2015.
3. Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142:46-54. e42; quiz e30.
4. Talley NJ, Abreu MT, Achkar JP, et al. An evidence-based systematic review on medical therapies for inflammatory bowel disease. American College of Gastroenterology IBD Task Force. Am J Gastroenterol. 2011; 106:S2-S25.
5. Loftus EV Jr, Shivashankar R, Tremaine W, Harmsen WS, Zinsmeister AR. Updated incidence and prevalence of Crohn’s disease and ulcerative colitis in Olmsted County, Minnesota (1970-2011). ACG 2014 Annual Scientific Meeting; October 2014.
6. Rocchi A, Benchimol EI, Bernstein CN, et al. Inflammatory bowel disease: a Canadian burden of illness review. Can J Gastroenterol. 2012;26:811-817.
7. Bernklev T, Jahnsen J, Schulz T, et al. Course of disease, drug treatment and health-related quality of life in patients with inflammatory bowel disease 5 years after initial diagnosis. Eur J Gastroenterol Hepatol. 2005;17:1037-1045.
8. Theede K, Kiszka-Kanowitz M, Nordgaard-Lassen I, Mertz Nielsen A. The impact of endoscopic inflammation and mucosal healing on health- related quality of life in ulcerative colitis patients. J Crohn s Colitis. 2015;9:625-632.
9. Wright EK, Kamm MA. Impact of drug therapy and surgery on qual ity of life in Crohn’s disease: a systematic review. Inflamm Bowel Dis. 2015;21:1187-1194.
10. McLean LP, Shea-Donohue T, Cross RK. Vedolizumab for the treat ment of ulcerative colitis and Crohn’s disease. Immunotherapy. 2012;4:883-898.
11. Cheng FK, McLean LP, Cross RK. What is the role of vedolizumab in the era of anti-TNF agents? Ann Transl Med. 2014;2:4.
12. Bressler B, Marshall JK, Bernstein CN, et al. Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus. Gastroenterology. 2015;148:1035-1058. e3.
13. Nguyen GC, Devlin SM, Afif W, et al. Defining quality indicators for best-practice management of inflammatory bowel disease in Canada. Can J Gastroenterol Hepatol. 2014;28:275-285.
14. Kaplan GG, Seow CH, Ghosh S, et al. Decreasing colectomy rates for ulcerative colitis: a population-based time trend study. Am J Gastroenterol. 2012;107:1879-1887.
15. Bernstein CN, Loftus EV Jr, Ng SC, et al. Hospitalisations and surgery in Crohn’s disease. Gut. 2012;61:622-629.
16. Singh S, Al-Darmaki A, Frolkis AD, et al. Post operative mortality among patients with inflammatory bowel diseases: a systematic review and meta-analysis of population-based studies. Gastroenterology. 2015;149:928-937.
17. van Dullemen HM, van Deventer SJ, Hommes DW, et al. Treatment of Crohn’s disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology. 1995;109:129-135.
18. Janssen. Remicade® (infliximab) Product monograph. 2014. Available from: http://www.janssen.ca/subcategory_docdownload?id=2263. Accessed July 15, 2015.
19. Abbvie. Humira® (adalimumab) Product monograph. 2015. Available from: http://www.abbvie.ca/content/dam/abbviecorp/ca/english/docs/HUMIRA_PM_EN.pdf. Accessed July 15, 2015.
20. Janssen. Simponi® (golimumab) Product monograph. 2014. Available from: http://www.janssen.ca/subcategory_docdownload?id=2278. Accessed July 15, 2015.
21. UCB Canada. Cimzia® (certolizumab pegol) Product monograph. 2014. Available from: http://www.ucb-canada.ca/_up/ucbpharma_ca_en/documents/cimzia_pm_en_15jan2014.pdf. Accessed July 15, 2015.
22. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance inflix imab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359:1541-1549.
23. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, aza- thioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010;362:1383-1395.
24. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necro-sis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology. 2006;130:323-333; quiz 591.
25. Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for main-tenance treatment of Crohn’s disease: results of the CLASSIC II trial. Gut. 2007;56:1232-1239.
26. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for main-tenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology. 2007;132:52-65.
27. Hyams J, Crandall W, Kugathasan S, et al. Induction and maintenance inf liximab therapy for the treatment of moderate-to-severe Crohn’s disease in children. Gastroenterology. 2007;132:863-873; quiz 1165-1166.
28. Hyams JS, Griffiths A, Markowitz J, et al. Safety and efficacy of adalimumab for moderate to severe Crohn’s disease in children. Gastroenterology. 2012;143:365-374. e2.
29. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med. 2004;350: 876-885.
30. Targan SR, Hanauer SB, van Deventer SJH, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosing factor a for Crohn’s disease. N Engl J Med. 1997;337(15):1029-1035.
31. Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab. Ann Intern Med. 2007;146(12):829-838.
32. Schreiber S, Rutgeerts P, Fedorak RN, et al. A randomized, placebo- controlled trial of certolizumab pegol (CDP870) for treatment of Crohn’s disease. Gastroenterology. 2005;129(3):807-818.
33. Sandborn WJ, Schreiber S, Feagan BG, et al. Certolizumab pegol for active Crohn’s disease: A placebo-controlled randomized trial. Clin Gastroenterol Hepatol. 2011;9(8):670-678.
34. Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab for Crohn’s disease. NEngl J Med. 2007;357: 239-250.
35. Sandborn WJ, Schreiber S, Feagan BG, et al. Certolizumab pegol for active Crohn’s disease: a placebo-controlled, randomized trial. Clin Gastroenterol Hepatol. 2011;9:670-678.
36. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353: 2462-2476.
37. Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcer ative colitis: results of a randomised controlled trial. Gut. 2011;60: 780-787.
38. Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012;142:257-2565. e1-e3.
39. Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate- to-severe ulcerative colitis. Gastroenterology. 2014;146:85-95; quiz e14-e15.
40. Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcer ative colitis. Gastroenterology. 2014;146:96-109. e1.
41. Hyams J, Damaraju L, Blank M, et al. Induction and maintenance therapy with infliximab for children with moderate to severe ulcerative colitis. Clin Gastroenterol Hepatol. 2012;10:391-399. e1.
42. Probert CSJ, Hearing SD, Schreiber S, et al. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised con trolled trial. Gut. 2003;52:998-1002.
43. Khanna R, Sattin BD, Afif W, et al. Review article: a clinician’s guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease. Aliment Pharmacol Ther. 2013;38:447-459.
44. Khanna R, Feagan BG. Current and future status of therapeutic drug monitoring in the treatment of IBD. Curr Treat Options Gastroenterol. 2014;12:76-89.
45. Sandborn WJ, Gasink C, Gao LL, et al. Ustekinumab induction and maintenance therapy in refractory Crohn’s disease. N Engl J Med. 2012;367:1519-1528.
46. Sandborn WJ, Feagan BG, Fedorak RN, et al. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn’s disease. Gastroenterology. 2008;135:1130-1141.
47. Lobaton T, Vermeire S, Van Assche G, Rutgeerts P. Review article: anti-adhesion therapies for inflammatory bowel disease. Aliment Pharmacol Ther. 2014;39:579-594.
48. Jaensson E, Uronen-Hansson H, Pabst O, et al. Small intestinal CD103+ dendritic cells display unique functional properties that are conserved between mice and humans. J Exp Med. 2008;205:2139-2149.
49. Agace W. Generation of gut-homing T cells and their localization to the small intestinal mucosa. Immunol Lett. 2010;128:21-23.
50. Agace WW. Tissue-tropic effector T cells: generation and targeting opportunities. Nat Rev Immunol. 2006;6:682-692.
51. Iwata M, Hirakiyama A, Eshima Y, Kagechika H, Kato C, Song SY Retinoic acid imprints gut-homing specificity on T cells. Immunity. 2004;21:527-538.
52. Mora JR, Iwata M, Eksteen B, et al. Generation of gut-homing IgA- secreting B cells by intestinal dendritic cells. Science. 2006;314: 1157-1160.
53. Agace WW. T-cell recruitment to the intestinal mucosa. Trends Immunol. 2008;29(11):541-552.
54. Butcher EC. Leukocyte-endothelial cell recognition: three (or more) steps to specificity and diversity. Cell. 1991;67:1033-1036.
55. Podolsky DK, Lobb R, King N, et al. Attenuation of colitis in the cotton-top tamarin by anti-alpha 4 integrin monoclonal antibody. J Clin Invest. 1993;92:372-380.
56. Biogen Canada. Tysabri® (natalizumab) Product Monograph 2015. Available from: http://www.biogen.ca/Admin/Public/DWSDownload.aspx?File=Files%2fFiler%2fCanada%2fProduct_Information%2fTYSABRI%2f2015_04_07-TYSABRI-PM-E.pdf Accessed July 15, 2015.
57. Postigo AA, Teixido J, Sanchez-Madrid F. The alpha 4 beta 1/VCAM-1 adhesion pathway in physiology and disease. Res Immunol. 1993;144:723-735; discussion 54-62.
58. Ghosh S, Goldin E, Gordon FH, et al. Natalizumab for active Crohn’s disease. N Engl J Med. 2003;348:24-32.
59. Yednock TA, Cannon C, Fritz LC, Sanchez-Madrid F, Steinman L, Karin N. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha4beta1 integrin. Nature. 1992;356:63-66.
60. Monaco MC, Major EO. The link between VLA-4 and JC virus reactivation. Expert Rev Clin Immunol. 2012;8:63-72.
61. Sandborn WJ, Colombel JF, Enns R, et al. Natalizumab induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2005;353: 1912-1925.
62. Soler D, Chapman T, Yang LL, Wyant T, Egan R, Fedyk ER. The binding specificity and selective antagonism of vedolizumab, an anti- {alpha}4{beta}7 integrin therapeutic antibody in development for inflam matory bowel diseases. J Pharmacol Exp Ther. 2009;330(3):864-875.
63. Gordon FH, Lai CWY, Hamilton MI, et al. A randomized placebo- controlled trial of a humanized monoclonal antibody to a4 integrin in active Crohn’s disease. Gastroenterology. 2001;121(2):268-274.
64. Targan SR, Feagan BG, Fedorak RN, et at. Natalizumab for the treatment of active Crohn’s disease: results of the ENCORE trial. Gastroenterology. 2007;132(5):1672-1683.
65. Sands BE, Korazek R, Spainhour J, et al. Safety and tolerability of con-current natalizumab treatment for patients with Crohn’s disease not in remission while receiving infliximab. Inflamm Bowel Dis. 2007;13(1): 2-11.
66. Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induc tion and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369:699-710.
67. Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2013;369: 711-721.
68. Sands BE, Feagan BG, Rutgeerts P, et al. Effects of vedolizumab induction therapy for patients with Crohn’s disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology. 2014;147: 618-627. e3.
69. Feagan BG, McDonald J, Greenberg G, et al. An ascending dose trial of a humanized alpha4 beta7 antibody in ulcerative colitis (UC). Gastroenterology. 2000;118(4):AB74.
70. Feagan BG, Greenberg G, Wild G, et al. 2005. Treatment of ulcerative colitis with a humanized antibody to the a4p7 integrin. N Engl J Med. 2005;352(24):2499-2507.
71. Feagan BG, Greenberg GR, Wild G, et al. Treatment of active Crohn’s disease with MLN0002, a humanized antibody to the a4p7 integrin. Clin Gastroenterol Hepatol. 2008;6(12):1370-1377.
72. Parikh A, Leach T, Wyant T, et al. Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging study. Inflamm Bowel Dis. 2012;18(8):1470-1479.
73. Hazlewood GS, Rezaie A, Borman M, et al. Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remis-sion in Crohn’s disease: a network meta-analysis. Gastroenterology. 2015;148:344-354. e5; quiz e14-e5.
74. Takeda. Entyvio® (vedolizumab) Product monograph. 2015. Available from: http://www.takedacanada.com/entyviopm7~/media/countries/ca/files/product%20pdfs/entyviopm_eng_2015jan25.pdf. Accessed July 15, 2015.
75. Wyant T, Leach T, Sankoh S, et al. Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results. Gut. 2015;64:77-83.
76. Hirschfield GM, Karlsen TH, Lindor KD, Adams DH. Primary scleros ing cholangitis. Lancet. 2013;382:1587-1599.
77. Eksteen B. Advances and controversies in the pathogenesis and management of primary sclerosing cholangitis. Br Med Bull. 2014;110:89-98.
78. Eksteen B, Miles AE, Grant AJ, Adams DH. Lymphocyte homing in the pathogenesis of extra-intestinal manifestations of inflammatory bowel disease. Clin Med. 2004;4:173-180.
79. Eksteen B, Grant AJ, Miles A, et al. Hepatic endothelial CCL25 medi-ates the recruitment of CCR9+ gut-homing lymphocytes to the liver in primary sclerosing cholangitis. J Exp Med. 2004;200:1511-1517.
80. Adams DH, Eksteen B. Aberrant homing of mucosal T cells and extra-intestinal manifestations of inflammatory bowel disease. Nat Rev Immunol. 2006;6:244-251.
81. Salmi M, Andrew DP, Butcher EC, Jalkanen S. Dual binding capac ity of mucosal immunoblasts to mucosal and synovial endothelium in humans: dissection of the molecular mechanisms. J Exp Med. 1995;181:137-149.
82. Salmi M, Jalkanen S. Endothelial ligands and homing of mucosal leu-kocytes in extraintestinal manifestations of IBD. Inflamm Bowel Dis. 1998;4:149-156.
83. Sandborn WJ, Ghosh S, Panes J, et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med. 2012;367: 616-624.
84. Bravata I, Fiorino G, Allocca M, Repici A, Danese S. New targeted therapies such as anti-adhesion molecules, anti-IL-12/23 and anti-Janus kinases are looking toward a more effective treatment of inflammatory bowel disease. Scand J Gastroenterol. 2015;50:113-120.
85. Rivera-Nieves J. Strategies that target leukocyte traffic in inflamma tory bowel diseases: recent developments. Curr Opin Gastroenterol. 2015;31:441-448.